Themis Bioscience

Themis Bioscience is a vaccine development company based in Vienna, Austria. The lead product is a vaccine against the tropical disease Chikungunya which is in late-stage clinical testing. In addition, Themis leveraged their vaccine platform technology to start developing a vaccine against Covid-19.

Themis Bioscience was acquired by MSD in May 2020.

Year of investment
2019

Year of exit
2020

Sector
Vaccines

Location
Vienna, Austria

Website
https://www.themisbio.com/